Alginate Microparticles for Vaccine Delivery

Suckow, Mark A.; Siger, L.; Bowersock, T. L.; Turek, John; Horne, D. Van; Borie, D.; Taylor, and Brian E.; Park, H.; Park, K.

doi:10.1021/bk-1999-0737.ch001

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The natural materials, collagen and alginate, have been processed into antigen-loaded microparticles that reduced the amount of antigen necessary to stimulate humoral immunity, and sustained this response for extended periods (Lofthouse et al 2001;Suckow et al 1999). Hydrophilic PLG microspheres of various molecular weights were demonstrated to control the release of antigen over 30-60 days, dependent on the period of time when the polymeric material was completely degraded by hydrolysis (Thomasin et al 1996).…”

Section: Antigen Delivery and DC Targetingmentioning

confidence: 99%

Immunologically Active Biomaterials for Cancer Therapy

Ali

Mooney

2010

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Our understanding of immunological regulation has progressed tremendously alongside the development of materials science, and at their intersection emerges the possibility to employ immunologically active biomaterials for cancer immunotherapy. Strong and sustained anticancer, immune responses are required to clear large tumor burdens in patients, but current approaches for immunotherapy are formulated as products for delivery in bolus, which may be indiscriminate and/or shortlived. Multifunctional biomaterial particles are now being developed to target and sustain antigen and adjuvant delivery to dendritic cells in vivo, and these have the potential to direct and prolong antigen-specific T cell responses. Three-dimensional immune cell niches are also being developed to regulate the recruitment, activation and deployment of immune cells in situ to promote potent antitumor responses. Recent studies demonstrate that materials with immune targeting and stimulatory capabilities can enhance the magnitude and duration of immune responses to cancer antigens, and preclinical results utilizing material-based immunotherapy in tumor models show a strong therapeutic benefit, justifying translation to and future testing in the clinic.

show abstract

Section: Antigen Delivery and DC Targetingmentioning

confidence: 99%